Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

En ECCMID 2014 se presentan los resultados del principal estudio sobre infección por Clostridium difficile


News provided by

Astellas Pharma Europe Ltd

02 May, 2014, 17:06 GMT

Share this article

Share toX

Share this article

Share toX

CHERTSEY, Inglaterra, May 2, 2014 /PRNewswire/ --

- Los primeros resultados completos del mayor estudio de prevalencia de la UE sobre infección por Clostridium difficile se presentarán en ECCMID 2014 

Elevada abundancia de datos del estudio EUCLID que se presentarán este año en ECCMID acerca de la infección por Clostridium difficile (CDI), una de las infecciones más comunes asociadas a los tratamientos de salud[1] 

El set completo de datos procedente de EUCLID, el mayor estudio de prevalencia jamás realizado de CDI en Europa, se presentará por primera vez en el 24th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) de Barcelona, España, del 10 al 13 de mayo de 2014.

Los datos se añadirán a los resultados iniciales de EUCLID presentados el año pasado, que destacan que la diagnosis incorrecta podría estar en uno de cada cinco pacientes hospitalizados con diarrea, que podrían tener CDI[2], y proporcionará una visión superior del alcance actual de la falta de pruebas y falta de detección de la infección por C. difficile en Europa.

Estos resultados tan esperados, que se compartirán por medio de las presentaciones orales y póster, están relacionadas también con los datos específicos de los países sobre la infección por C. difficile, una enfermedad potencialmente mortal. La CDI es una de las causas más habituales de diarrea asociadas a los antibióticos, y los casos más severos pueden necesitar de cirugía intestinal e incluso producir la muerte[1]. Los pacientes de hospital con CDI tienen hasta tres veces más de posibilidades de fallecer en un hospital (o al mes de la infección) frente a los que no padecen CDI[3],[4].

El estudio de punto de prevalencia europeo multicentro, prospectivo y bianual de Clostridium difficile Infection in hospitalised patients with Diarrhoea (EUCLID) ha implicado a 482 hospitales de 20 países de Europa. El estudio lo está coordinando la University of Leeds, Reino Unido, por medio del grupo de investigación del profesor Mark Wilcox, con el apoyo del EUCLID Core Group. El estudio cuenta con fondos de Astellas Pharma Europe Ltd.

Visión general de los abstractos que se presentarán en ECCMID:

  • Second report from the European, multi-centre, prospective bi-annual point prevalence study of Clostridium difficile Infection in hospitalised patients with Diarrhoea (EUCLID).
    • Presentación póster:P0753, Sesión póster III 
    • Domingo 11 de mayo a las 13:30, Área de póster 
  • Increased diversity of C. difficile PCR-ribotypes across European countries and disparity of 027 prevalence; Results of the European, multi-centre, prospective bi-annual point prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID).
    • Presentación oral:O002 
    • Sábado 10 de mayo a las 13:42, HALL E 
  • Analysis of actual Clostridium difficile epidemiology in Germany based on a multi-centre, bi-annual point prevalence study in European countries (EUCLID)
    • Presentación oral:O010 
    • Sábado 10 de mayo a las 1315:18, HALL E 
  • Optimised diagnosis of Clostridium difficile infection; is there still room for improvement? Results of a European point prevalence study of C. difficile infection (EUCLID).
    • Presentación póster:P0738, Sesión póster III 
    • Domingo 11 de mayo a las 13:30, Área de póster 
  • Italian preliminary data obtained from the European, multi-centre, prospective bi-annual point prevalence study of Clostridium difficile infection in hospitalised patients with Diarrhoea (EUCLID).
    • Presentación póster:P0758, Sesión póster III 
    • Domingo 11 de mayo a las 13:30, Área de póster 
  • Efficacy of tapered fidaxomicin dosing regimens to treat simulated Clostridium difficile infection (CDI) in an in vitro gut model 
    • Presentación póster:P0797, Sesión póster III 
    • Domingo 11 de mayo a las 13:30, Área de póster 
  • Persistence and removal of fidaxomicin from C. difficile spores, and impact on spore recovery
    • Presentación póster:P0799, Sesión póster III 
    • Domingo 11 de mayo a las 13:30, Área de póster 
  • Point-prevalence of Clostridium difficile infections (CDI) in Greek hospitals: a cross-sectional study 
    • Presentación póster:P0757, Sesión póster III 
    • Domingo 11 de mayo a las 13:30, Área de póster 
  • Use of allelic exchange to characterise the impact of three separate mutations in rpoB on the fitness of Clostridium difficile and sensitivity to fidaxomicin
    • Presentación póster:P0808, Sesión póster III 
    • Domingo 11 de mayo a las 13:30, Área de póster 

Acerca de la infección por Clostridium difficile 

La infección por CDI es una enfermedad grave causada por la infección de la línea interna del colon por la bacteria C. difficile. La bacteria produce toxinas que causan la inflamación del colon, diarrea y, en algunos casos, la muerte[5]. Los pacientes suelen desarrollar la CDI por el uso de antibióticos de amplio espectro que interrumpen la flora intestinal normal, permitiendo que se multiplique la bacteria C. difficile[5],[6]. CDI es la principal causa de diarrea adquirida en hospital (nosocomial) en los países industrializados[7] y el riesgo de CDI y de recurrencia de la enfermedad es particularmente elevado en los pacientes de 65 año y mayores[8]. La recurrencia de CDI ocurre en hasta un 25% de pacientes dentro de los 30 días de inicio del tratamiento con las terapias actuales[9],[10],[11]. La ESCMID ha identificado la recurrencia como el problema más importante en el tratamiento de CDI[12].

Acerca de Astellas Pharma Europe Ltd.   

Astellas Pharma Europe Ltd., con sede en el Reino Unido, es una filial europea de Astellas Pharma Inc., una empresa con sede en Tokio. Astellas es una empresa farmacéutica dedicada a mejorar la salud de personas de todo el mundo mediante el suministro de fármacos innovadores y fiables. La compañía tiene como objetivo convertirse en una empresa global que combine capacidades extraordinarias de I+D y marketing y continúe creciendo en el mercado mundial farmacéutico. Astellas Pharma Europe Ltd. es responsable de 21 empresas afiliadas situadas en Europa, Oriente Medio y África, la compañía tienen una instalación de I+D y tres plantas de producción en Europa. La compañía cuenta con una plantilla de aproximadamente 4.300 empleados en estas regiones. Para más información sobre Astellas Pharma Europe, visite http://www.astellas.eu.

Referencias   

1. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8:17-26. 

2. Davies K et al. First report from European, multi-centre, prospective bi-annual point prevalence study of Clostridium difficile Infection in hospitalised patients with Diarrhoea (EUCLID). Póster tardio LB-2968 presentado en el European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Berlín, Alemania, del 27 al 30 de abril de 2013. 

3. Oake N, et al. The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. Arch Intern Med 2010;170:1804-10. 

4. Hensgens MP, et al. All-Cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a Multicenter Cohort Study. Clin Infect Dis. 2013;56:1108-16. 

5. Poutanen SM et al. Clostridium difficile-associated diarrhoea in adults. CMAJ. 2004;171:51-8. 

6. Kelly CP et al. Clostridium difficile infection. Ann Rev Med. 1998;49:375-390. 

7. Crobach MJ, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile infection (CDI). Clinical Microbiology and Infection 2009;15:1053-1066. 

8. Pepin J, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-7. 

9. Bouza E, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin Micro Infect. 2008;14(Suppl 7):S103-4. 

10. Lowy I, et al. Treatment with Monoclonal Antibodies against Clostridium difficile Toxins. N Engl J Med. 2010;362;3:197-205. 

11. Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-31.

12. Bauer MP, et al. European Society of Clinical Microbiology and Infectious Disease (ESCMID): treatment guidance document for Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009;15:1067-79. 

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.